139 related articles for article (PubMed ID: 34302713)
21. Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.
Martin-Guerrero I; Salaverria I; Burkhardt B; Chassagne-Clement C; Szczepanowski M; Bens S; Klapper W; Zimmermann M; Kabickova E; Bertrand Y; Reiter A; Siebert R; Oschlies I
Genes Chromosomes Cancer; 2019 Jun; 58(6):365-372. PubMed ID: 30578714
[TBL] [Abstract][Full Text] [Related]
22. Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia.
Filippidou M; Avgerinou G; Katsibardi K; Gavra M; Pons R; Kattamis A
Pediatr Blood Cancer; 2021 Jul; 68(7):e29040. PubMed ID: 33788389
[No Abstract] [Full Text] [Related]
23. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
[TBL] [Abstract][Full Text] [Related]
24. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
26. Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia.
Kersun LS; Wimmer RS; Hoot AC; Meadows AT
Pediatr Blood Cancer; 2004 Mar; 42(3):289-91. PubMed ID: 14752871
[No Abstract] [Full Text] [Related]
27. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
[TBL] [Abstract][Full Text] [Related]
28. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
29. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Landmann E; Burkhardt B; Zimmermann M; Meyer U; Woessmann W; Klapper W; Wrobel G; Rosolen A; Pillon M; Escherich G; Attarbaschi A; Beishuizen A; Mellgren K; Wynn R; Ratei R; Plesa A; Schrappe M; Reiter A; Bergeron C; Patte C; Bertrand Y
Haematologica; 2017 Dec; 102(12):2086-2096. PubMed ID: 28983060
[TBL] [Abstract][Full Text] [Related]
30. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia.
Takanashi M; Morimoto A; Yagi T; Kuriyama K; Kano G; Imamura T; Hibi S; Todo S; Imashuku S
Haematologica; 2003 Nov; 88(11):1238-44. PubMed ID: 14607752
[TBL] [Abstract][Full Text] [Related]
31. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
O'Leary MC; Lu X; Huang Y; Lin X; Mahmood I; Przepiorka D; Gavin D; Lee S; Liu K; George B; Bryan W; Theoret MR; Pazdur R
Clin Cancer Res; 2019 Feb; 25(4):1142-1146. PubMed ID: 30309857
[TBL] [Abstract][Full Text] [Related]
33. MLL duplication in a pediatric patient with B-cell lymphoblastic lymphoma.
Mater DV; Goodman BK; Wang E; Gaca AM; Wechsler DS
J Pediatr Hematol Oncol; 2012 Apr; 34(3):e120-3. PubMed ID: 22052166
[TBL] [Abstract][Full Text] [Related]
34. [Comparative evaluation of blast cell proliferation and effectiveness of combined chemotherapy in children with different immunocytological subvariants of acute lymphoblastic and nonlymphoblastic leukemia].
Golenko OD; Tupitsyn NN; Protasova AK; Balakirev SA; Kochetkova OD
Gematol Transfuziol; 1989 Sep; 34(9):24-8. PubMed ID: 2583457
[TBL] [Abstract][Full Text] [Related]
35. [Cutaneous involvement as the form of presentation in B-cell lymphoblastic leukemia/lymphoma].
López Almaraz R; Raya Sánchez JM; Domínguez Suárez M; Brito Barroso Mf Mf; Rodríguez Luis J
An Esp Pediatr; 2002 Dec; 57(6):578-81. PubMed ID: 12466084
[TBL] [Abstract][Full Text] [Related]
36. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.
Gaipa G; Basso G; Aliprandi S; Migliavacca M; Vallinoto C; Maglia O; Faini A; Veltroni M; Husak D; Schumich A; Ratei R; Biondi A; Dworzak MN;
Cytometry B Clin Cytom; 2008 May; 74(3):150-5. PubMed ID: 18271020
[TBL] [Abstract][Full Text] [Related]
37. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
[TBL] [Abstract][Full Text] [Related]
38. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
39. Lymphoid malignancies following Kawasaki disease.
Murray JC; Bomgaars LR; Carcamo B; Mahoney DH
Am J Hematol; 1995 Dec; 50(4):299-300. PubMed ID: 7485107
[TBL] [Abstract][Full Text] [Related]
40. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
Mullighan CG
Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
